Supplementary Tables 1 through 4 and Supplementary Figures 1 through 8 from Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells Article Swipe

View

Elliott J. Brea , Claire Y. Oh , Eusebio Manchado , Sadna Budhu , Ron S. Gejman , George Mo , Patrizia Mondello , James E. Han , Casey A. Jarvis , David Ulmert , Qing Xiang , Aaron Y. Chang , Ralph Garippa , Taha Merghoub , Jedd D. Wolchok , Neal Rosen , Scott W. Lowe , David A. Scheinberg ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/2326-6066.22537259

Supplementary Table S1. MSK Memorial Hospital IMPACT genomic sequencing data for the JMN human mesothelioma cell line. Supplementary Table S2. Sh RNA used. Supplementary Table S3. List of antibodies used. Supplementary Table S4. Top 5 negative regulatory and top 5 positive regulatory kinase genes that were hits from the screen for regulating surface HLA-A expression. Supplementary Figure S1. Knockdown of HLA-A causes resistance to antibody dependent cellular cytotoxicity by the ESK-M mAb. Supplementary Figure S2. Coordinated regulation of total surface HLA-A, B, and C with knockdown of either MAP2K1 of EGFR. Supplementary Figure S3. Validation of MAP2K1, EGFR, and RET as negative kinase regulators in mesothelioma cell lines. Supplementary Figure S4. DDR2 and MINK1 acts as positive regulators of surface HLA-A. Supplementary Figure S5. Treatment with IFN gamma and/or kinase inhibitors, afatinib or trametinib, on cells with mutant EFGR (H1975) or mutant BRAF (SK-Mel5 and UACC257). Supplementary Figure S6. Viability of JMN after treatment with MEKi trametinib and EGFRi Afatinib. Supplementary Figure S7. Titration of trametinib to determine optimal inhibition of MEK using pERK as a marker of inhibition. Supplementary Figure S8. JMN was treated with 50 nM trametinib and lysate was analyzed as in Figure 4C at different time points.

Related Topics

Major Histocompatibility Complex

Concepts

Trametinib MEK inhibitor Gene knockdown Cancer research Kinase MHC class I MAPK/ERK pathway Biology Cell culture Molecular biology Major histocompatibility complex Gene Genetics

Metadata

Type: supplementary-materials
Language: en
Landing Page: https://doi.org/10.1158/2326-6066.22537259
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4362551696

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4362551696

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/2326-6066.22537259

Digital Object Identifier
Title: Supplementary Tables 1 through 4 and Supplementary Figures 1 through 8 from Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

Work title
Type: supplementary-materials

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-04-03

Full publication date if available
Authors: Elliott J. Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert, Qing Xiang, Aaron Y. Chang, Ralph Garippa, Taha Merghoub, Jedd D. Wolchok, Neal Rosen, Scott W. Lowe, David A. Scheinberg

List of authors in order
Landing page: https://doi.org/10.1158/2326-6066.22537259

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/2326-6066.22537259

Direct OA link when available
Concepts: Trametinib, MEK inhibitor, Gene knockdown, Cancer research, Kinase, MHC class I, MAPK/ERK pathway, Biology, Cell culture, Molecular biology, Major histocompatibility complex, Gene, Genetics

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4362551696
doi	https://doi.org/10.1158/2326-6066.22537259
ids.doi	https://doi.org/10.1158/2326-6066.22537259
ids.openalex	https://openalex.org/W4362551696
fwci
type	supplementary-materials
title	Supplementary Tables 1 through 4 and Supplementary Figures 1 through 8 from Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T14099
topics[0].field.id	https://openalex.org/fields/16
topics[0].field.display_name	Chemistry
topics[0].score	0.8883000016212463
topics[0].domain.id	https://openalex.org/domains/3
topics[0].domain.display_name	Physical Sciences
topics[0].subfield.id	https://openalex.org/subfields/1605
topics[0].subfield.display_name	Organic Chemistry
topics[0].display_name	Synthesis and Characterization of Heterocyclic Compounds
topics[1].id	https://openalex.org/T11215
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.8752999901771545
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2720
topics[1].subfield.display_name	Hematology
topics[1].display_name	Chronic Myeloid Leukemia Treatments
topics[2].id	https://openalex.org/T12318
topics[2].field.id	https://openalex.org/fields/16
topics[2].field.display_name	Chemistry
topics[2].score	0.8539000153541565
topics[2].domain.id	https://openalex.org/domains/3
topics[2].domain.display_name	Physical Sciences
topics[2].subfield.id	https://openalex.org/subfields/1605
topics[2].subfield.display_name	Organic Chemistry
topics[2].display_name	Quinazolinone synthesis and applications
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2778472372
concepts[0].level	4
concepts[0].score	0.9238967299461365
concepts[0].wikidata	https://www.wikidata.org/wiki/Q7833138
concepts[0].display_name	Trametinib
concepts[1].id	https://openalex.org/C2781249067
concepts[1].level	4
concepts[1].score	0.6585183143615723
concepts[1].wikidata	https://www.wikidata.org/wiki/Q17142288
concepts[1].display_name	MEK inhibitor
concepts[2].id	https://openalex.org/C173396325
concepts[2].level	3
concepts[2].score	0.6506307125091553
concepts[2].wikidata	https://www.wikidata.org/wiki/Q1501275
concepts[2].display_name	Gene knockdown
concepts[3].id	https://openalex.org/C502942594
concepts[3].level	1
concepts[3].score	0.503095805644989
concepts[3].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[3].display_name	Cancer research
concepts[4].id	https://openalex.org/C184235292
concepts[4].level	2
concepts[4].score	0.4715668857097626
concepts[4].wikidata	https://www.wikidata.org/wiki/Q421851
concepts[4].display_name	Kinase
concepts[5].id	https://openalex.org/C170627219
concepts[5].level	4
concepts[5].score	0.43153083324432373
concepts[5].wikidata	https://www.wikidata.org/wiki/Q13218497
concepts[5].display_name	MHC class I
concepts[6].id	https://openalex.org/C57074206
concepts[6].level	3
concepts[6].score	0.4204917550086975
concepts[6].wikidata	https://www.wikidata.org/wiki/Q14197552
concepts[6].display_name	MAPK/ERK pathway
concepts[7].id	https://openalex.org/C86803240
concepts[7].level	0
concepts[7].score	0.37988218665122986
concepts[7].wikidata	https://www.wikidata.org/wiki/Q420
concepts[7].display_name	Biology
concepts[8].id	https://openalex.org/C81885089
concepts[8].level	2
concepts[8].score	0.3572709560394287
concepts[8].wikidata	https://www.wikidata.org/wiki/Q189082
concepts[8].display_name	Cell culture
concepts[9].id	https://openalex.org/C153911025
concepts[9].level	1
concepts[9].score	0.35083135962486267
concepts[9].wikidata	https://www.wikidata.org/wiki/Q7202
concepts[9].display_name	Molecular biology
concepts[10].id	https://openalex.org/C207936829
concepts[10].level	3
concepts[10].score	0.2758827805519104
concepts[10].wikidata	https://www.wikidata.org/wiki/Q423163
concepts[10].display_name	Major histocompatibility complex
concepts[11].id	https://openalex.org/C104317684
concepts[11].level	2
concepts[11].score	0.22016799449920654
concepts[11].wikidata	https://www.wikidata.org/wiki/Q7187
concepts[11].display_name	Gene
concepts[12].id	https://openalex.org/C54355233
concepts[12].level	1
concepts[12].score	0.20451638102531433
concepts[12].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[12].display_name	Genetics
keywords[0].id	https://openalex.org/keywords/trametinib
keywords[0].score	0.9238967299461365
keywords[0].display_name	Trametinib
keywords[1].id	https://openalex.org/keywords/mek-inhibitor
keywords[1].score	0.6585183143615723
keywords[1].display_name	MEK inhibitor
keywords[2].id	https://openalex.org/keywords/gene-knockdown
keywords[2].score	0.6506307125091553
keywords[2].display_name	Gene knockdown
keywords[3].id	https://openalex.org/keywords/cancer-research
keywords[3].score	0.503095805644989
keywords[3].display_name	Cancer research
keywords[4].id	https://openalex.org/keywords/kinase
keywords[4].score	0.4715668857097626
keywords[4].display_name	Kinase
keywords[5].id	https://openalex.org/keywords/mhc-class-i
keywords[5].score	0.43153083324432373
keywords[5].display_name	MHC class I
keywords[6].id	https://openalex.org/keywords/mapk/erk-pathway
keywords[6].score	0.4204917550086975
keywords[6].display_name	MAPK/ERK pathway
keywords[7].id	https://openalex.org/keywords/biology
keywords[7].score	0.37988218665122986
keywords[7].display_name	Biology
keywords[8].id	https://openalex.org/keywords/cell-culture
keywords[8].score	0.3572709560394287
keywords[8].display_name	Cell culture
keywords[9].id	https://openalex.org/keywords/molecular-biology
keywords[9].score	0.35083135962486267
keywords[9].display_name	Molecular biology
keywords[10].id	https://openalex.org/keywords/major-histocompatibility-complex
keywords[10].score	0.2758827805519104
keywords[10].display_name	Major histocompatibility complex
keywords[11].id	https://openalex.org/keywords/gene
keywords[11].score	0.22016799449920654
keywords[11].display_name	Gene
keywords[12].id	https://openalex.org/keywords/genetics
keywords[12].score	0.20451638102531433
keywords[12].display_name	Genetics
language	en
locations[0].id	doi:10.1158/2326-6066.22537259
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/2326-6066.22537259
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5035010583
authorships[0].author.orcid	https://orcid.org/0000-0002-6283-0267
authorships[0].author.display_name	Elliott J. Brea
authorships[0].author_position	first
authorships[0].raw_author_name	Elliott J. Brea
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5072042134
authorships[1].author.orcid
authorships[1].author.display_name	Claire Y. Oh
authorships[1].author_position	middle
authorships[1].raw_author_name	Claire Y. Oh
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5036401196
authorships[2].author.orcid	https://orcid.org/0009-0009-3170-9788
authorships[2].author.display_name	Eusebio Manchado
authorships[2].author_position	middle
authorships[2].raw_author_name	Eusebio Manchado
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5082626339
authorships[3].author.orcid	https://orcid.org/0000-0002-3284-1408
authorships[3].author.display_name	Sadna Budhu
authorships[3].author_position	middle
authorships[3].raw_author_name	Sadna Budhu
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5029670586
authorships[4].author.orcid	https://orcid.org/0000-0001-5138-2772
authorships[4].author.display_name	Ron S. Gejman
authorships[4].author_position	middle
authorships[4].raw_author_name	Ron S. Gejman
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5067313194
authorships[5].author.orcid	https://orcid.org/0009-0009-0677-3147
authorships[5].author.display_name	George Mo
authorships[5].author_position	middle
authorships[5].raw_author_name	George Mo
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5046495281
authorships[6].author.orcid	https://orcid.org/0000-0002-0355-3757
authorships[6].author.display_name	Patrizia Mondello
authorships[6].author_position	middle
authorships[6].raw_author_name	Patrizia Mondello
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5032404829
authorships[7].author.orcid	https://orcid.org/0000-0002-0417-3879
authorships[7].author.display_name	James E. Han
authorships[7].author_position	middle
authorships[7].raw_author_name	James E. Han
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5006257943
authorships[8].author.orcid	https://orcid.org/0000-0001-9598-6615
authorships[8].author.display_name	Casey A. Jarvis
authorships[8].author_position	middle
authorships[8].raw_author_name	Casey A. Jarvis
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5081366346
authorships[9].author.orcid	https://orcid.org/0000-0002-7871-2281
authorships[9].author.display_name	David Ulmert
authorships[9].author_position	middle
authorships[9].raw_author_name	David Ulmert
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5100741589
authorships[10].author.orcid	https://orcid.org/0000-0002-7953-8246
authorships[10].author.display_name	Qing Xiang
authorships[10].author_position	middle
authorships[10].raw_author_name	Qing Xiang
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5073815714
authorships[11].author.orcid	https://orcid.org/0000-0002-7770-7405
authorships[11].author.display_name	Aaron Y. Chang
authorships[11].author_position	middle
authorships[11].raw_author_name	Aaron Y. Chang
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5086601654
authorships[12].author.orcid	https://orcid.org/0000-0003-3917-0739
authorships[12].author.display_name	Ralph Garippa
authorships[12].author_position	middle
authorships[12].raw_author_name	Ralph J. Garippa
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5002951130
authorships[13].author.orcid	https://orcid.org/0000-0002-1518-5111
authorships[13].author.display_name	Taha Merghoub
authorships[13].author_position	middle
authorships[13].raw_author_name	Taha Merghoub
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5054656505
authorships[14].author.orcid	https://orcid.org/0000-0001-6718-2222
authorships[14].author.display_name	Jedd D. Wolchok
authorships[14].author_position	middle
authorships[14].raw_author_name	Jedd D. Wolchok
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5060228803
authorships[15].author.orcid	https://orcid.org/0000-0002-8307-654X
authorships[15].author.display_name	Neal Rosen
authorships[15].author_position	middle
authorships[15].raw_author_name	Neal Rosen
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5025451142
authorships[16].author.orcid	https://orcid.org/0000-0002-5284-9650
authorships[16].author.display_name	Scott W. Lowe
authorships[16].author_position	middle
authorships[16].raw_author_name	Scott W. Lowe
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5006680533
authorships[17].author.orcid	https://orcid.org/0000-0002-4160-923X
authorships[17].author.display_name	David A. Scheinberg
authorships[17].author_position	last
authorships[17].raw_author_name	David A. Scheinberg
authorships[17].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/2326-6066.22537259
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Tables 1 through 4 and Supplementary Figures 1 through 8 from Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T14099
primary_topic.field.id	https://openalex.org/fields/16
primary_topic.field.display_name	Chemistry
primary_topic.score	0.8883000016212463
primary_topic.domain.id	https://openalex.org/domains/3
primary_topic.domain.display_name	Physical Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1605
primary_topic.subfield.display_name	Organic Chemistry
primary_topic.display_name	Synthesis and Characterization of Heterocyclic Compounds
related_works	https://openalex.org/W1968485788, https://openalex.org/W3033847543, https://openalex.org/W2312667856, https://openalex.org/W2125845533, https://openalex.org/W4313880234, https://openalex.org/W4322726652, https://openalex.org/W3108755209, https://openalex.org/W2469570005, https://openalex.org/W4361935873, https://openalex.org/W4362542650
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/2326-6066.22537259
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/2326-6066.22537259
primary_location.id	doi:10.1158/2326-6066.22537259
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/2326-6066.22537259
publication_date	2023-04-03
publication_year	2023
referenced_works_count	0
abstract_inverted_index.5	34, 39
abstract_inverted_index.C	83
abstract_inverted_index.a	175
abstract_inverted_index.4C	196
abstract_inverted_index.50	186
abstract_inverted_index.B,	81
abstract_inverted_index.Sh	20
abstract_inverted_index.as	100, 115, 174, 193
abstract_inverted_index.at	197
abstract_inverted_index.by	68
abstract_inverted_index.in	104, 194
abstract_inverted_index.nM	187
abstract_inverted_index.of	27, 59, 77, 86, 89, 95, 118, 150, 164, 170, 177
abstract_inverted_index.on	134
abstract_inverted_index.or	132, 140
abstract_inverted_index.to	63, 166
abstract_inverted_index.IFN	126
abstract_inverted_index.JMN	12, 151, 182
abstract_inverted_index.MEK	171
abstract_inverted_index.MSK	3
abstract_inverted_index.RET	99
abstract_inverted_index.RNA	21
abstract_inverted_index.S1.	2, 57
abstract_inverted_index.S2.	19, 74
abstract_inverted_index.S3.	25, 93
abstract_inverted_index.S4.	32, 110
abstract_inverted_index.S5.	123
abstract_inverted_index.S6.	148
abstract_inverted_index.S7.	162
abstract_inverted_index.S8.	181
abstract_inverted_index.Top	33
abstract_inverted_index.and	37, 82, 98, 112, 144, 157, 189
abstract_inverted_index.for	10, 50
abstract_inverted_index.the	11, 48, 69
abstract_inverted_index.top	38
abstract_inverted_index.was	183, 191
abstract_inverted_index.BRAF	142
abstract_inverted_index.DDR2	111
abstract_inverted_index.EFGR	138
abstract_inverted_index.List	26
abstract_inverted_index.MEKi	155
abstract_inverted_index.acts	114
abstract_inverted_index.cell	15, 106
abstract_inverted_index.data	9
abstract_inverted_index.from	47
abstract_inverted_index.hits	46
abstract_inverted_index.mAb.	71
abstract_inverted_index.pERK	173
abstract_inverted_index.that	44
abstract_inverted_index.time	199
abstract_inverted_index.were	45
abstract_inverted_index.with	84, 125, 136, 154, 185
abstract_inverted_index.EGFR,	97
abstract_inverted_index.EGFR.	90
abstract_inverted_index.EGFRi	158
abstract_inverted_index.ESK-M	70
abstract_inverted_index.HLA-A	53, 60
abstract_inverted_index.MINK1	113
abstract_inverted_index.Table	1, 18, 24, 31
abstract_inverted_index.after	152
abstract_inverted_index.cells	135
abstract_inverted_index.gamma	127
abstract_inverted_index.genes	43
abstract_inverted_index.human	13
abstract_inverted_index.line.	16
abstract_inverted_index.total	78
abstract_inverted_index.used.	22, 29
abstract_inverted_index.using	172
abstract_inverted_index.Figure	56, 73, 92, 109, 122, 147, 161, 180, 195
abstract_inverted_index.HLA-A,	80
abstract_inverted_index.HLA-A.	120
abstract_inverted_index.IMPACT	6
abstract_inverted_index.MAP2K1	88
abstract_inverted_index.and/or	128
abstract_inverted_index.causes	61
abstract_inverted_index.either	87
abstract_inverted_index.kinase	42, 102, 129
abstract_inverted_index.lines.	107
abstract_inverted_index.lysate	190
abstract_inverted_index.marker	176
abstract_inverted_index.mutant	137, 141
abstract_inverted_index.screen	49
abstract_inverted_index.(H1975)	139
abstract_inverted_index.MAP2K1,	96
abstract_inverted_index.genomic	7
abstract_inverted_index.optimal	168
abstract_inverted_index.surface	52, 79, 119
abstract_inverted_index.treated	184
abstract_inverted_index.(SK-Mel5	143
abstract_inverted_index.Hospital	5
abstract_inverted_index.Memorial	4
abstract_inverted_index.afatinib	131
abstract_inverted_index.analyzed	192
abstract_inverted_index.antibody	64
abstract_inverted_index.cellular	66
abstract_inverted_index.negative	35, 101
abstract_inverted_index.positive	40, 116
abstract_inverted_index.Afatinib.	159
abstract_inverted_index.Knockdown	58
abstract_inverted_index.Titration	163
abstract_inverted_index.Treatment	124
abstract_inverted_index.UACC257).	145
abstract_inverted_index.Viability	149
abstract_inverted_index.dependent	65
abstract_inverted_index.determine	167
abstract_inverted_index.different	198
abstract_inverted_index.knockdown	85
abstract_inverted_index.treatment	153
abstract_inverted_index.Validation	94
abstract_inverted_index.antibodies	28
abstract_inverted_index.inhibition	169
abstract_inverted_index.regulating	51
abstract_inverted_index.regulation	76
abstract_inverted_index.regulators	103, 117
abstract_inverted_index.regulatory	36, 41
abstract_inverted_index.resistance	62
abstract_inverted_index.sequencing	8
abstract_inverted_index.trametinib	156, 165, 188
abstract_inverted_index.Coordinated	75
abstract_inverted_index.expression.	54
abstract_inverted_index.inhibition.	178
abstract_inverted_index.inhibitors,	130
abstract_inverted_index.trametinib,	133
abstract_inverted_index.cytotoxicity	67
abstract_inverted_index.mesothelioma	14, 105
abstract_inverted_index.Supplementary	17, 23, 30, 55, 72, 91, 108, 121, 146, 160, 179
abstract_inverted_index.points.</p>	200
abstract_inverted_index.<p>Supplementary	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	18
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.7799999713897705
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.06441656
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False